Management of Hyperglycemia in Type 2 Diabetes, 2018.
A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Davies M, D’Alessio,D Fradkin J et al
Diabetes Care 2018 Sep dci180033
https://doi.org/10.2337/dci18-0033
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott S, Raz I, Bonaca et al for the DECLARE–TIMI 58 Investigators
The New England Journal of Medicine Downloaded from nejm.org on November 12, 2018.
https://www.nejm.org/doi/full/10.1056/NEJMoa1812389
Glycemic Control and Risk of Infections Among People With Type 1 or Type 2 Diabetes in a Large Primary Care Cohort Study.
Critchley JA, Carey IM, Harris T, DeWilde S, Hosking FJ, Cook DG.
Diabetes Care. 2018 Oct;41(10):2127-2135.
https://doi.org/10.2337/dc18-0287.
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
Stefan N, Häring HU, Cusi K.
Lancet Diabetes Endocrinol. 2018 Aug 30. pii: S2213-8587(18)30154-2.
https://doi.org/10.1016/S2213-8587(18)30154-2
Unique challenges of cystic fibrosis‐related diabetes
Bridges N, Rowe R, Holt H
Diabetic Medicine April 2018 : 35(9)1181-1188
https://doi.org/10.1111/dme.13652
Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Rawshani A et al
N Engl J Med 2018; 379:633-644
https://doi.org/10.1056/NEJMoa1800256
Comentarios recientes